Funding for this research was provided by:
the Kock Foundation
Spenshult Research and Development Centre
The Swedish Rheumatism Association
Received: 2 January 2022
Accepted: 14 March 2022
First Online: 25 May 2022
: Ethical approval was granted by the Regional Ethics Committee in Lund, Sweden (Dnr 301/2007, 406/2008, 2011/547 and 2013/128), and an informed written consent was obtained from all patients, in accordance with the Declaration of Helsinki.
: Not applicable.
: Elisabeth Mogard: Consultant for Novartis (unrelated to the present work). Ann Bremander: None declared. Emma Haglund: Consultant for Novartis (unrelated to the present work).